| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_56f9a65bed3331f36d136aaf45d7cbcb |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-585
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-567
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-585
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565 |
| filingDate |
2005-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2010-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da71308c2477d0b331bb94b432977c68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e72c0a38b7e5963577146d5003b942a1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5965e15745be83c59a3e19319198033c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ec86372423f82ad44f5def1b0c7bc96 |
| publicationDate |
2010-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2396082-C2 |
| titleOfInvention |
Multiphase pharmaceutical preparation for ovulation inhibition in mammal |
| abstract |
FIELD: medicine. n SUBSTANCE: multiphase pharmaceutical preparation for ovulation inhibition in mammal contains a number of individually packed and individually removed daily units placed in a single package, and used for oral administration for at least 21 days running; specified daily units contain a combination of oestradiol and drospirenone. A daily unit contains 0.5 to 4 mg of oestradiol and 2 to 4 mg of drospirenone. At least 70% of specified drospirenone are released from specified unit within 30 minutes. n EFFECT: invention provides higher oral bioavailability of drospirenone. n 6 cl, 5 dwg, 5 ex |
| priorityDate |
1999-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |